ZA97452B - Streptococcus equi vaccine. - Google Patents

Streptococcus equi vaccine.

Info

Publication number
ZA97452B
ZA97452B ZA9700452A ZA97452A ZA97452B ZA 97452 B ZA97452 B ZA 97452B ZA 9700452 A ZA9700452 A ZA 9700452A ZA 97452 A ZA97452 A ZA 97452A ZA 97452 B ZA97452 B ZA 97452B
Authority
ZA
South Africa
Prior art keywords
vaccine
streptococcus equi
equi vaccine
preparation
relates
Prior art date
Application number
ZA9700452A
Other languages
English (en)
Inventor
Orla Mary Hartford
Timothy James Foster
Antonius Arnodus Christ Jacobs
Original Assignee
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8223610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA97452(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trinity College Dublin filed Critical Trinity College Dublin
Publication of ZA97452B publication Critical patent/ZA97452B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA9700452A 1996-01-25 1997-01-20 Streptococcus equi vaccine. ZA97452B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200171 1996-01-25

Publications (1)

Publication Number Publication Date
ZA97452B true ZA97452B (en) 1997-08-15

Family

ID=8223610

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9700452A ZA97452B (en) 1996-01-25 1997-01-20 Streptococcus equi vaccine.

Country Status (16)

Country Link
US (1) US5895654A (ru)
EP (1) EP0786518B1 (ru)
JP (1) JP3911058B2 (ru)
AT (1) ATE219511T1 (ru)
AU (1) AU703942B2 (ru)
BR (1) BRPI9700768B8 (ru)
CA (1) CA2195935C (ru)
CZ (1) CZ289530B6 (ru)
DE (1) DE69713408T2 (ru)
DK (1) DK0786518T3 (ru)
ES (1) ES2179261T3 (ru)
NZ (1) NZ314091A (ru)
PL (1) PL187163B1 (ru)
PT (1) PT786518E (ru)
RU (1) RU2194752C2 (ru)
ZA (1) ZA97452B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6682745B1 (en) 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE1033998T1 (de) * 1997-12-03 2001-05-23 Brigham And Women's Hospital, Boston Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
ES2214217T3 (es) * 1999-01-26 2004-09-16 Akzo Nobel N.V. Utilizacion de bacterias vivas atenuadas para la preparacion de una vacuna de administracion por la submucosa.
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP5889529B2 (ja) * 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0801326D0 (en) 2008-01-24 2008-03-05 Animal Health Trust Vaccines
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
GB201209014D0 (en) * 2012-05-22 2012-07-04 Moredun Res Inst Vaccine
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9089560B2 (en) 2013-02-01 2015-07-28 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
EP3057613A1 (en) 2013-10-17 2016-08-24 Zoetis Services LLC Methods and compositions for treatment of s. equi infection
EP2949340A1 (en) * 2014-05-30 2015-12-02 IDT Biologika GmbH Vaccine composition against Streptococcus suis infection
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
JP2022505950A (ja) 2018-10-26 2022-01-14 オキュフィア・ファーマ・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110433A (en) * 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4582798A (en) * 1984-11-23 1986-04-15 Miles Laboratories, Inc. Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
AR241545A1 (es) 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
US4788059A (en) * 1985-07-15 1988-11-29 Coopers Animal Health, Inc. Equine strangles vaccine and the method of preparing and using the same
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
WO1989003427A1 (en) * 1987-10-07 1989-04-20 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
EP0626452B1 (en) * 1993-05-17 1999-08-11 Akzo Nobel N.V. Vaccine against Streptococcus suis infection
DE69417717T2 (de) * 1993-12-20 1999-10-07 Akzo Nobel N.V., Arnheim/Arnhem Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen

Also Published As

Publication number Publication date
CA2195935C (en) 2006-06-27
EP0786518A1 (en) 1997-07-30
US5895654A (en) 1999-04-20
ATE219511T1 (de) 2002-07-15
PT786518E (pt) 2002-10-31
DE69713408D1 (de) 2002-07-25
BRPI9700768B1 (pt) 2008-11-04
CZ289530B6 (cs) 2002-02-13
BRPI9700768B8 (pt) 2016-11-16
JP3911058B2 (ja) 2007-05-09
BR9700768A (pt) 1998-11-03
AU703942B2 (en) 1999-04-01
CA2195935A1 (en) 1997-07-26
NZ314091A (en) 1998-06-26
AU1234697A (en) 1997-08-07
DE69713408T2 (de) 2002-11-21
PL318095A1 (en) 1997-08-04
DK0786518T3 (da) 2002-09-16
EP0786518B1 (en) 2002-06-19
ES2179261T3 (es) 2003-01-16
CZ21497A3 (cs) 1998-03-18
PL187163B1 (pl) 2004-05-31
RU2194752C2 (ru) 2002-12-20
JPH09215492A (ja) 1997-08-19

Similar Documents

Publication Publication Date Title
PL318095A1 (en) Streptococcus equi vaccine
MY113428A (en) Hepatitis b vaccine
DK199901675A (da) Fremgangsmåder til revnedannelse i underjordiske formationer
ZA917771B (en) Oligosaccharide conjugate vaccines
CA2138137A1 (en) Diphtheria toxin vaccines
MY125202A (en) Vaccine
IL118603A0 (en) Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
GB9713156D0 (en) Vaccines
CA2243755A1 (en) Streptococcal c5a peptidase vaccine
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
BG101131A (en) 2-oxo-and 2-thio-1,2-dihydroquinolinyl-oxazolidinons
WO1998056901A3 (en) Live attenuated vaccines
GB9422096D0 (en) Combined meningitis vaccine
ZA934736B (en) Deletion mutants as vaccines for cholera
GB9808327D0 (en) Antidiotypic compounds
EP0771214A4 (en) TREATMENT AND PREVENTION OF HELICOBACTER INFECTIONS
AP2000001886A0 (en) Group B streptococcus antigens.
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
ZA938171B (en) Conjugate vaccine against group B Streptococcus.
AU1801195A (en) Antigenic preparation for treatment or prevention of helicobacter infection
AU2002217043A1 (en) Salmonella vaccine
IL125797A0 (en) Parapoxviruses which contain foreign dna their preparation and their use in vaccines
BG100248A (en) Squalene synthetase inhibitors
AU7498896A (en) Lactic starters and use thereof for preparing cholesterol-lowering products
CA2243730A1 (en) Streptococcus equi vaccine